English
Stock of the day
Telix Pharmaceuticals navigates FDA resubmission amid market uncertainty
Telix Pharmaceuticals faces market volatility as it resubmits its FDA application for a brain cancer imaging agent.
(AI video summary)
This video was created on 9 September 2025 for IG audiences by ausbiz.
ASX code: TLX
Telix Pharmaceuticals faces uncertainty with FDA resubmission
Telix Pharmaceuticals announced an agreement with the United States Food and Drug Administration (FDA) to resubmit its application for a brain cancer imaging agent. The market reacted nervously after Telix reported FDA challenges that necessitate additional efficacy analysis for the resubmission.
Investors are split on the recent share price drop, debating whether it's a 'falling knife' or a buying opportunity.
Investment outlook
Analysts describe the FDA approval process as unpredictable. Telix’s market valuation includes anticipated sales from a second product yet to materialise. Caution is suggested due to current risks and the need for discounts.
Telix's high debt-to-equity ratio, exceeding 100%, raises concerns as it seeks more capital. Historically, biotech investments, except a few like CSL in New Zealand, have had mixed results. Such investments are often speculative, akin to relying on hope.
Important to know
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Ready to open an IG account?
Start your trading journey now
Contact
New clients
1800 601 799
newaccounts.au@ig.com
Existing clients
1800 601 799
newaccounts.au@ig.com
Lines open
24/7 except 6am to 12pm Saturdays (AEST)
Start a Whatsapp chat
Connect with us
Disclaimers
- CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You do not own or have any interest in the underlying asset. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. Please consider the Margin Trading Product Disclosure Statement (PDS), Risk Disclosure Notice and Target Market Determination before entering into any CFD transaction with us.
- The value of shares, ETFs and ETCs bought through an IG share trading account can fall as well as rise, which could mean getting back less than you originally put in. Past performance is no guarantee of future results.
- Please ensure you fully understand the risks and take care to manage your exposure.
- The information on this website is prepared without considering your objectives, financial situation or needs. Consequently, you should consider the information in light of your objectives, financial situation and needs.
- This website is operated by IG Australia Pty Ltd. IG Australia Pty Ltd is located on Level 32, Queen & Collins, 376-390 Collins Street, Melbourne, VIC 3000. ABN 93 096 585 410, Australian Financial Services Licence No. 515106. Derivatives Issuer Licence in New Zealand FSP No. 684191, NZBN 9429047618251.